1. Home
  2. ATNM vs SACH Comparison

ATNM vs SACH Comparison

Compare ATNM & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • SACH
  • Stock Information
  • Founded
  • ATNM 2000
  • SACH 2010
  • Country
  • ATNM United States
  • SACH United States
  • Employees
  • ATNM N/A
  • SACH N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • SACH Real Estate Investment Trusts
  • Sector
  • ATNM Health Care
  • SACH Real Estate
  • Exchange
  • ATNM Nasdaq
  • SACH Nasdaq
  • Market Cap
  • ATNM 51.5M
  • SACH 46.2M
  • IPO Year
  • ATNM N/A
  • SACH 2017
  • Fundamental
  • Price
  • ATNM $1.54
  • SACH $0.99
  • Analyst Decision
  • ATNM Strong Buy
  • SACH Hold
  • Analyst Count
  • ATNM 3
  • SACH 3
  • Target Price
  • ATNM $4.67
  • SACH $2.25
  • AVG Volume (30 Days)
  • ATNM 229.8K
  • SACH 287.8K
  • Earning Date
  • ATNM 05-09-2025
  • SACH 05-01-2025
  • Dividend Yield
  • ATNM N/A
  • SACH 18.24%
  • EPS Growth
  • ATNM N/A
  • SACH N/A
  • EPS
  • ATNM N/A
  • SACH N/A
  • Revenue
  • ATNM N/A
  • SACH N/A
  • Revenue This Year
  • ATNM N/A
  • SACH N/A
  • Revenue Next Year
  • ATNM N/A
  • SACH $4.52
  • P/E Ratio
  • ATNM N/A
  • SACH N/A
  • Revenue Growth
  • ATNM N/A
  • SACH N/A
  • 52 Week Low
  • ATNM $1.03
  • SACH $0.80
  • 52 Week High
  • ATNM $8.64
  • SACH $3.16
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 49.81
  • SACH 52.18
  • Support Level
  • ATNM $1.56
  • SACH $0.90
  • Resistance Level
  • ATNM $1.69
  • SACH $0.98
  • Average True Range (ATR)
  • ATNM 0.11
  • SACH 0.05
  • MACD
  • ATNM -0.01
  • SACH 0.01
  • Stochastic Oscillator
  • ATNM 32.18
  • SACH 93.37

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

Share on Social Networks: